Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
featured
AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443) and Sorafenib (IND# 69896) for Patients with High Allelic Ratio FLT3/ITD

AAML1031, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443) and Sorafenib (IND# 69896) for Patients with High Allelic Ratio FLT3/ITD

  • 368 views
  • 08 Nov, 2020
  • 1 location
Role of the Therapy Tailored to Risk Factors in Treating Adult Patients ( 60) With Acute Myeloid Leukemia

In view of the diversity of the biology of acute myeloid leukemia (AML) therapy in individual patients must be individualized. One of the tools for this is molecular-cytogenetic stratification. It divides patients into five categories (prognostic groups): Favorable, Intermediate-1, Intermediate-2, Adverse and Very adverse risk. After remission proceedings are tailored …

filgrastim
ara-c
colony stimulating factor
granulocyte colony stimulating factor
mitoxantrone
  • 19 views
  • 08 Nov, 2020
  • 1 location
HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.

This is a non-randomized prospective open-label single-arm clinical phase I trial investigating dose finding, feasibility and safety of the combined treatment of HDM201 and midostaurin in patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3mut applying an accelerated titration design.

  • 0 views
  • 27 Jan, 2021
  • 1 location
Safety and Effectiveness of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML) a Cancer of the Blood

Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Children or young adults with a certain kind of blood cancer (FLT3-ITD

flt3 internal tandem duplication
cancer
hematologic malignancy
blast cells
induction chemotherapy
  • 39 views
  • 15 Apr, 2021
  • 39 locations
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

is better, 2) to study the effects, good and/or bad, of adding gilteritinib to AML therapy for patients with high amounts of FLT3/ITD or other FLT3 mutations and 3) to study changes in heart function

cytarabine/daunorubicin
cancer
gemtuzumab
cell transplantation
anthracyclines
  • 5 views
  • 25 Mar, 2021
  • 75 locations
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

study. They will also be positive for FLT3-ITD mutation. Participants will receive a combined dose of quizartinib and milademetan that have not been approved by the US Food and Drug

flt3 internal tandem duplication
remission
induction chemotherapy
  • 31 views
  • 25 Jan, 2021
  • 10 locations
Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD

In this multicenter, upfront randomized phase II trial, all patients receive quizartinib in combination with HAM (high-dose cytarabine, mitoxantrone) during salvage therapy. Efficacy is assessed by comparison to historical controls based on the matched threshold crossing approach. During consolidation therapy (chemotherapy as well as allo-HCT) patients receive either prophylactic quizartinib …

  • 0 views
  • 28 Jan, 2021
  • 1 location
Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients

Recent advances in acute myeloid leukemia (AML) have been characterized by a better understanding of disease biology. As such, FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD

  • 0 views
  • 23 Jan, 2021
  • 11 locations
AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance

Prospective, multi-center, interventional, randomized, open clinical trial for the treatment of acute myeloid leukemia with FLT3 mutations customized upon the prognostic parameter PBC

  • 0 views
  • 26 Jan, 2021
  • 1 location
A Clinical Trial to Evaluate Clifutinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia(AML)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of Clifutinib Besylate in Relapsed/refractory AML patients with FLT3-ITD

  • 0 views
  • 08 Apr, 2021
  • 1 location